Abstracts tagged "rheumatoid arthritis (RA) and psoriatic arthritis"

Abstract Number: 99 • ACR/ARP Annual Meeting 2019
Mass Cytometry Immunophenotyping of Synovial Fluid from Checkpoint Inhibitor Related Arthritis
Runci Wang¹, Karmela Kim Chan ², Amy Cunningham-Bussel ³, Laura Donlin ⁴, Gregory Vitone ², Aidan Tirpack ², Caroline Benson ², Gregory Keras ³, Anna Helena Jonsson ⁵, Michael Brenner ⁶, Anne Bass ⁷ and Deepak Rao ¹, ¹Brigham and women's hospital, Boston, MA, ²Hospital For Special Surgery, New York, ³Brigham and women's hospital, Boston, ⁴Hospital For Special Surgery, New York, NY, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women’s Hospital:, Boston, ⁷Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Anti-PD-1/PD-L1 checkpoint inhibitor therapies have produced remarkable results in stimulating immune responses against tumors. Checkpoint inhibitor therapy can also trigger a variety of autoimmune…
Abstract Number: 536 • ACR/ARP Annual Meeting 2019
PERFUSE: A French Prospective/Retrospective Non-interventional Cohort Study of Infliximab-naïve and Transitioned Patients Receiving Infliximab Biosimilar SB2; An Interim Analysis
Bruno Fautrel¹, Yoram Bouhnik ², Guillaume Desjeux ³, Ulrich Freudensprung ⁴, Janet Addison ⁵ and Amira Brigui ⁶, ¹Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ²Beaujon Hospital, Department of Gastroenterology, AP-HP, Paris Diderot University, Clichy, France, ³E-health Services Sanoïa, Digital CRO, Gémenos, France, ⁴Biogen International GmbH, Zug, Switzerland, ⁵Biogen UK, Maidenhead, United Kingdom, ⁶Biogen France SAS, Paris, France
Background/Purpose: SB2 is approved in the EU as an infliximab (IFX) biosimilar, having demonstrated bioequivalence and similar efficacy, safety and immunogenicity as the reference. There…
Abstract Number: 2095 • ACR/ARP Annual Meeting 2019
A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients
Kieran Murray¹, Candice Low ¹, Francis Young ¹, Anna O'Rourke ¹, Ian Callanan ², Eoin Feeney ¹ and Douglas Veale ³, ¹Saint Vincent's University Hospital, Dublin, Ireland, ²Saint Vincent's University Hospital, Dublin, Dublin, Ireland, ³EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: The ACR and CDC recommend influenza (“flu”) and 23-valent pneumococcal polysaccharide (PPSV23) vaccination for inflammatory arthritis (IA) patients on immunosuppression. This study aimed to:…
Abstract Number: 2256 • ACR/ARP Annual Meeting 2019
Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
W. Benjamin Nowell¹, Elaine Karis ², Kelly Gavigan ¹, Laura Stradford ¹, Scott Stryker ³, Shilpa Venkatachalam ¹, Gregory Kricorian ³ and Jeffrey Curtis ⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Amgen Inc, Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) is a frequently used therapy in both Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) due to its beneficial effects in both populations.…